Differential Action on Coregulator Interaction Defines Inverse Retinoid Agonists and Neutral Antagonists

Chemistry and Biology

Volumn 16, Issue 5, 2009, Pages 479-489

  Germain, Pierre ^a,b,c   Gaudon, Claudine ^a   Pogenberg, Vivian ^b,c   Sanglier, Sarah ^d   Van Dorsselaer, Alain ^d   Royer, Catherine A ^b,c   Lazar, Mitchell A ^e   Bourguet, William ^b,c   Gronemeyer, Hinrich ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b INSERM   (France)

^c CNRS   (France)

^d INSTITUT DE RECHERCHES SUBATOMIQUES   (France)

^e Institute for Diabetes   (United States)

Author keywords

CELLBIO; CHEMBIO; SIGNALING

Indexed keywords

4 (2 (5,6 DIHYDRO 5,5 DIMETHYL 8 (2 PHENYLETHYNYL)NAPHTHALEN 2 YL)ETHEN 1 YL)BENZOIC ACID; 4 (5,6 DIHYDRO 5,5 DIMETHYL 8 (QUINOLIN 3 YL)NAPHTHALEN 2 CARBOXAMIDO)BENZOIC ACID; 4 AMINOBENZOIC ACID; 4-(2-(5,6-DIHYDRO-5,5-DIMETHYL-8-(2-PHENYLETHYNYL)NAPHTHALEN-2-YL)ETHEN-1-YL)BENZOIC ACID; 4-(5,6-DIHYDRO-5,5-DIMETHYL-8-(QUINOLIN-3-YL)NAPHTHALEN-2-CARBOXAMIDO)BENZOIC ACID; BENZOIC ACID DERIVATIVE; DRUG DERIVATIVE; MUTANT PROTEIN; QUINOLINE DERIVATIVE; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR ALPHA; STILBENE DERIVATIVE;

ARTICLE; CHEMISTRY; DRUG ANTAGONISM; HELA CELL; HUMAN; INVERSE AGONISM; METABOLISM; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

4-AMINOBENZOIC ACID; BENZOIC ACIDS; CELL LINE, TUMOR; DRUG INVERSE AGONISM; HELA CELLS; HUMANS; MUTANT PROTEINS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; QUINOLINES; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTOR ALPHA; STILBENES;

EID: 65949085164     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2009.03.008     Document Type: Article

References (44)

1. Alland L., Muhle R., Hou H., Potes J., Chin L., Schreiber-Agus N., and DePinho R.A. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature 387 (1997) 49-55
2. Altucci L., and Gronemeyer H. The promise of retinoids to fight against cancer. Nat. Rev. Cancer 1 (2001) 181-193
3. Altucci L., Leibowitz M.D., Ogilvie K.M., de Lera A.R., and Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat. Rev. Drug Discov. 6 (2007) 793-810
4. Astapova I., Lee L.J., Morales C., Tauber S., Bilban M., and Hollenberg A.N. The nuclear corepressor, NCoR, regulates thyroid hormone action in vivo. Proc. Natl. Acad. Sci. USA 105 (2008) 19544-19549
5. Bourguet W., Andry V., Iltis C., Klaholz B., Potier N., Van Dorsselaer A., Chambon P., Gronemeyer H., and Moras D. Heterodimeric complex of RAR and RXR nuclear receptor ligand-binding domains: purification, crystallization, and preliminary X-Ray diffraction asnalysis. Protein Expr. Purif. 19 (2000) 284-288
6. Bourguet W., Germain P., and Gronemeyer H. Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol. Sci. 21 (2000) 381-388
7. Bourguet W., Vivat V., Wurtz J.M., Chambon P., Gronemeyer H., and Moras D. Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol. Cell 5 (2000) 289-298
8. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J. 10 (1996) 940-954
9. Chen J.D., and Evans R.M. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377 (1995) 454-457
10. Cohen R.N., Brzostek S., Kim B., Chorev M., Wondisford F.E., and Hollenberg A.N. The specificity of interactions between nuclear hormone receptors and corepressors is mediated by distinct amino acid sequences within the interacting domains. Mol. Endocrinol. 15 (2001) 1049-1061
11. Dawson M.I. Synthetic retinoids and their nuclear receptors. Curr. Med. Chem. Anticancer Agents 4 (2004) 199-230
12. de Lera A.R., Bourguet W., Altucci L., and Gronemeyer H. Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat. Rev. Drug Discov. 6 (2007) 811-820
13. Evert B.O., Araujo J., Vieira-Saecker A.M., de Vos R.A., Harendza S., Klockgether T., and Wullner U. Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation. J. Neurosci. 26 (2006) 11474-11486
14. Germain P., Iyer J., Zechel C., and Gronemeyer H. Coregulator recruitment and the mechanism of retinoic acid receptor synergy. Nature 415 (2002) 187-192
15. Germain P., Kammerer S., Perez E., Peluso-Iltis C., Tortolani D., Zusi F.C., Starrett J., Lapointe P., Daris J.P., Marinier A., et al. Rational design of RAR-selective ligands revealed by RARbeta crystal stucture. EMBO Rep. 5 (2004) 877-882
16. Germain P., Chambon P., Eichele G., Evans R.M., Lazar M.A., Leid M., De Lera A.R., Lotan R., Mangelsdorf D.J., and Gronemeyer H. International Union of Pharmacology. LX. Retinoic acid receptors. Pharmacol. Rev. 58 (2006) 712-725
17. Gronemeyer H., Gustafsson J.A., and Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 3 (2004) 950-964
18. Heinzel T., Lavinsky R.M., Mullen T.M., Soderstrom M., Laherty C.D., Torchia J., Yang W.M., Brard G., Ngo S.D., Davie J.R., et al. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387 (1997) 43-48
19. Horlein A.J., Naar A.M., Heinzel T., Torchia J., Gloss B., Kurokawa R., Ryan A., Kamei Y., Soderstrom M., Glass C.K., et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377 (1995) 397-404
20. Hu X., and Lazar M.A. The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature 402 (1999) 93-96
21. Jepsen K., Solum D., Zhou T., McEvilly R.J., Kim H.J., Glass C.K., Hermanson O., and Rosenfeld M.G. SMRT-mediated repression of an H3K27 demethylase in progression from neural stem cell to neuron. Nature 450 (2007) 415-419
22. Klein E.S., Pino M.E., Johnson A.T., Davies P.J., Nagpal S., Thacher S.M., Krasinski G., and Chandraratna R.A. Identification and functional separation of retinoic acid receptor neutral antagonists and inverse agonists. J. Biol. Chem. 271 (1996) 22692-22696
23. Lin B.C., Hong S.H., Krig S., Yoh S.M., and Privalsky M.L. A conformational switch in nuclear hormone receptors is involved in coupling hormone binding to corepressor release. Mol. Cell. Biol. 17 (1997) 6131-6138
24. Liu Z., Auboeuf D., Wong J., Chen J.D., Tsai S.Y., Tsai M.J., and O'Malley B.W. Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc. Natl. Acad. Sci. USA 99 (2002) 7940-7944
25. Lonard D.M., and O'Malley B.W. Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol. Cell 27 (2007) 691-700
26. Mark M., Ghyselinck N.B., and Chambon P. Function of retinoid nuclear receptors: lessons from genetic and pharmacological dissections of the retinoic acid signaling pathway during mouse embryogenesis. Annu. Rev. Pharmacol. Toxicol. 46 (2006) 451-480
27. Melnick A., Carlile G., Ahmad K.F., Kiang C.L., Corcoran C., Bardwell V., Prive G.G., and Licht J.D. Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors. Mol. Cell. Biol. 22 (2002) 1804-1818
28. Nagpal S., Friant S., Nakshatri H., and Chambon P. RARs and RXRs: evidence for two autonomous transactivation functions (AF-1 and AF-2) and heterodimerization in vivo. EMBO J. 12 (1993) 2349-2360
29. Nagy L., Kao H.Y., Chakravarti D., Lin R.J., Hassig C.A., Ayer D.E., Schreiber S.L., and Evans R.M. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89 (1997) 373-380
30. Nagy L., Kao H.Y., Love J.D., Li C., Banayo E., Gooch J.T., Krishna V., Chatterjee K., Evans R.M., and Schwabe J.W. Mechanism of corepressor binding and release from nuclear hormone receptors. Genes Dev. 13 (1999) 3209-3216
31. Nofsinger R.R., Li P., Hong S.H., Jonker J.W., Barish G.D., Ying H., Cheng S.Y., Leblanc M., Xu W., Pei L., et al. SMRT repression of nuclear receptors controls the adipogenic set point and metabolic homeostasis. Proc. Natl. Acad. Sci. USA 105 (2008) 20021-20026
32. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., and Milburn M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395 (1998) 137-143
33. Perissi V., Staszewski L.M., McInerney E.M., Kurokawa R., Krones A., Rose D.W., Lambert M.H., Milburn M.V., Glass C.K., and Rosenfeld M.G. Molecular determinants of nuclear receptor-corepressor interaction. Genes Dev. 13 (1999) 3198-3208
34. Pike A.C., Brzozowski A.M., Walton J., Hubbard R.E., Thorsell A.G., Li Y.L., Gustafsson J.A., and Carlquist M. Structural insights into the mode of action of a pure antiestrogen. Structure 9 (2001) 145-153
35. Pogenberg V., Guichou J.F., Vivat-Hannah V., Kammerer S., Perez E., Germain P., de Lera A.R., Gronemeyer H., Royer C.A., and Bourguet W. Characterization of the interaction between retinoic acid receptor/retinoid X receptor (RAR/RXR) heterodimers and transcriptional coactivators through structural and fluorescence anisotropy studies. J. Biol. Chem. 280 (2005) 1625-1633
36. Rosenfeld M.G., Lunyak V.V., and Glass C.K. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. 20 (2006) 1405-1428
37. Sande S., and Privalsky M.L. Identification of TRACs (T3 receptor-associating cofactors), a family of cofactors that associate with, and modulate the activity of, nuclear hormone receptors. Mol. Endocrinol. 10 (1996) 813-825
38. Schulman I.G., Li C., Schwabe J.W., and Evans R.M. The phantom ligand effect: allosteric control of transcription by the retinoid X receptor. Genes Dev. 11 (1997) 299-308
39. Seol W., Mahon M.J., Lee Y.K., and Moore D.D. Two receptor interacting domains in the nuclear hormone receptor corepressor RIP13/N-CoR. Mol. Endocrinol. 10 (1996) 1646-1655
40. Shulman A.I., and Mangelsdorf D.J. Retinoid x receptor heterodimers in the metabolic syndrome. N. Engl. J. Med. 353 (2005) 604-615
41. Vivat V., Gofflo D., Garcia T., Wurtz J.M., Bourguet W., Philibert D., and Gronemeyer H. Sequences in the ligand-binding domains of the human androgen and progesterone receptors which determine their distinct ligand identities. J. Mol. Endocrinol. 18 (1997) 147-160
42. Voegel J.J., Heine M.J., Tini M., Vivat V., Chambon P., and Gronemeyer H. The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO J. 17 (1998) 507-519
43. Xu H.E., Stanley T.B., Montana V.G., Lambert M.H., Shearer B.G., Cobb J.E., McKee D.D., Galardi C.M., Plunket K.D., Nolte R.T., et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature 415 (2002) 813-817
44. Zamir I., Harding H.P., Atkins G.B., Horlein A., Glass C.K., Rosenfeld M.G., and Lazar M.A. A nuclear hormone receptor corepressor mediates transcriptional silencing by receptors with distinct repression domains. Mol. Cell. Biol. 16 (1996) 5458-5465